Literature DB >> 29580569

Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.

Jennifer W Evans1, Joanna Szczepanik2, Nancy Brutsché2, Lawrence T Park2, Allison C Nugent2, Carlos A Zarate2.   

Abstract

BACKGROUND: The symptoms of major depressive disorder (MDD) are rapidly alleviated by administration of a single dose of the glutamatergic modulator ketamine. However, few studies have investigated the potential sustained neural effects of this agent beyond immediate infusion. This study used functional magnetic resonance imaging to examine the effect of a single ketamine infusion on the resting state default mode network (DMN) at 2 and 10 days after a single ketamine infusion in unmedicated subjects with MDD as well as healthy control subjects (HCs).
METHODS: Data were drawn from a double-blind, placebo-controlled crossover study of 58 participants (33 with MDD and 25 HCs) who received an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 separate test days spaced 2 weeks apart. Eight minutes of functional magnetic resonance imaging resting state data was acquired at baseline and at about 2 and 10 days after both infusions. The DMN was defined using seed-based correlation and was compared across groups and scans.
RESULTS: In subjects with MDD, connectivity between the insula and the DMN was normalized compared with HCs 2 days postketamine infusion. This change was reversed after 10 days and did not appear in either of the placebo scans. Group-specific connectivity differences in drug response were observed, most notably in the insula in subjects with MDD and in the thalamus in HCs.
CONCLUSIONS: Connectivity changes in the insula in subjects with MDD suggest that ketamine may normalize the interaction between the DMN and salience networks, supporting the triple network dysfunction model of MDD. Published by Elsevier Inc.

Entities:  

Keywords:  Default mode network; Functional magnetic resonance imaging (fMRI); Glutamatergic modulator; Ketamine; Major depressive disorder; Resting state

Mesh:

Substances:

Year:  2018        PMID: 29580569      PMCID: PMC6093808          DOI: 10.1016/j.biopsych.2018.01.027

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  50 in total

Review 1.  The restless brain.

Authors:  Marcus E Raichle
Journal:  Brain Connect       Date:  2011

2.  A critical role for the right fronto-insular cortex in switching between central-executive and default-mode networks.

Authors:  Devarajan Sridharan; Daniel J Levitin; Vinod Menon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

3.  Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus.

Authors:  Michael D Greicius; Benjamin H Flores; Vinod Menon; Gary H Glover; Hugh B Solvason; Heather Kenna; Allan L Reiss; Alan F Schatzberg
Journal:  Biol Psychiatry       Date:  2007-01-08       Impact factor: 13.382

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents.

Authors:  O M Doyle; S De Simoni; A J Schwarz; C Brittain; O G O'Daly; S C R Williams; M A Mehta
Journal:  J Pharmacol Exp Ther       Date:  2013-01-31       Impact factor: 4.030

6.  Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers.

Authors:  S De Simoni; A J Schwarz; O G O'Daly; A F Marquand; C Brittain; C Gonzales; S Stephenson; S C R Williams; M A Mehta
Journal:  Neuroimage       Date:  2012-09-23       Impact factor: 6.556

7.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

8.  Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.

Authors:  J W Murrough; K A Collins; J Fields; K E DeWilde; M L Phillips; S J Mathew; E Wong; C Y Tang; D S Charney; D V Iosifescu
Journal:  Transl Psychiatry       Date:  2015-02-17       Impact factor: 6.222

9.  Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.

Authors:  Milan Scheidegger; Martin Walter; Mick Lehmann; Coraline Metzger; Simone Grimm; Heinz Boeker; Peter Boesiger; Anke Henning; Erich Seifritz
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

10.  Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.

Authors:  N R Driesen; G McCarthy; Z Bhagwagar; M Bloch; V Calhoun; D C D'Souza; R Gueorguieva; G He; R Ramachandran; R F Suckow; A Anticevic; P T Morgan; J H Krystal
Journal:  Mol Psychiatry       Date:  2013-01-22       Impact factor: 15.992

View more
  38 in total

1.  Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder.

Authors:  Allison C Nugent; Cristan Farmer; Jennifer W Evans; Sam L Snider; Dipavo Banerjee; Carlos A Zarate
Journal:  Hum Brain Mapp       Date:  2019-06-09       Impact factor: 5.038

Review 2.  Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.

Authors:  Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuron       Date:  2019-04-03       Impact factor: 17.173

3.  Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants.

Authors:  Jessica L Reed; Allison C Nugent; Maura L Furey; Joanna E Szczepanik; Jennifer W Evans; Carlos A Zarate
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-01-25

Review 4.  Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review.

Authors:  Ilya Demchenko; Vanessa K Tassone; Sidney H Kennedy; Katharine Dunlop; Venkat Bhat
Journal:  Front Psychiatry       Date:  2022-05-26       Impact factor: 5.435

5.  Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects.

Authors:  Meng Li; Marie Woelfer; Lejla Colic; Adam Safron; Catie Chang; Hans-Jochen Heinze; Oliver Speck; Helen S Mayberg; Bharat B Biswal; Giacomo Salvadore; Anna Fejtova; Martin Walter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-10-23       Impact factor: 5.270

Review 6.  Suicide Has Many Faces, So Does Ketamine: a Narrative Review on Ketamine's Antisuicidal Actions.

Authors:  Aiste Lengvenyte; Emilie Olié; Philippe Courtet
Journal:  Curr Psychiatry Rep       Date:  2019-12-03       Impact factor: 5.285

7.  Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment.

Authors:  Christoph Kraus; Anahit Mkrtchian; Bashkim Kadriu; Allison C Nugent; Carlos A Zarate; Jennifer W Evans
Journal:  Neuropsychopharmacology       Date:  2020-01-29       Impact factor: 7.853

Review 8.  Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.

Authors:  Bashkim Kadriu; Maximillian Greenwald; Ioline D Henter; Jessica R Gilbert; Christoph Kraus; Lawrence T Park; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

Review 9.  Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology.

Authors:  Alexandra A Alario; Mark J Niciu
Journal:  Chronic Stress (Thousand Oaks)       Date:  2021-05-31

Review 10.  Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Authors:  Gustavo A Angarita; Hasti Hadizadeh; Ignacio Cerdena; Marc N Potenza
Journal:  Expert Opin Pharmacother       Date:  2021-06-23       Impact factor: 4.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.